Our study has some limitations, including that only CSF proteins of MS patients were screened, while the corresponding serum samples were not assessed for the proteomics analysis of the discovery cohort, and it was unknown whether IGFBP7 and SST levels were affected by therapy. This evidence concerns the gene IGFBP7 and myeloid sarcoma.